Cutler Group LP Bio N Tech Se Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$118.43 - $186.05 $108,008 - $169,677	912 Added 43.68%	3,000 $450,000
Q3 2022 Oct 25, 2022	SELL	$127.65 - $183.11 $73,398 - $105,288	-575 Reduced 21.59%	2,088 $281,000
Q2 2022 Aug 04, 2022	SELL	$123.25 - $186.24 $3.74 Million - $5.65 Million	-30,333 Reduced 91.93%	2,663 $397,000
Q1 2022 Apr 14, 2022	BUY	$126.25 - $231.85 $2.58 Million - $4.74 Million	20,429 Added 162.56%	32,996 $5.63 Million
Q4 2021 Jan 18, 2022	BUY	$216.64 - $362.52 $1.88 Million - $3.14 Million	8,667 Added 222.23%	12,567 $3.24 Million
Q3 2021 Oct 26, 2021	BUY	$205.93 - $447.23 $39,950 - $86,762	194 Added 5.23%	3,900 $1.06 Million
Q2 2021 Jul 19, 2021	SELL	$113.32 - $241.49 $351,745 - $749,584	-3,104 Reduced 45.58%	3,706 $829,000
Q1 2021 Apr 26, 2021	BUY	$85.73 - $119.5 $274,936 - $383,236	3,207 Added 89.01%	6,810 $743,000
Q4 2020 Jan 21, 2021	BUY	$72.71 - $129.54 $145,638 - $259,468	2,003 Added 125.19%	3,603 $293,000
Q3 2020 Oct 27, 2020	BUY	$57.81 - $104.17 $92,496 - $166,672	1,600 New	1,600 $110,000

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.